Hiroshi Kuriki

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone et al. · Journal of Thoracic Oncology · 2021 · 187 citations

Medicine, Pharmacology, Immune Checkpoint Inhibitor +7

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

David R. Spigel, Filippo de Marinis, Giuseppe Giaccone et al. · Annals of Oncology · 2019 · 144 citations

Pd-l1–selected Nsclc, Oncology, Medicine +9

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong et al. · Blood · 2018 · 130 citations · Full text

Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study

Nozomu Fuse, Hideaki Bando, Keisho Chìn et al. · Gastric Cancer · 2016 · 81 citations · Full text